GPT Healthcare Ltd Q4 FY26 Earnings Analysis

- Company expects sustained double-digit growth in most hospitals, including Howrah, Agartala, and Salt Lake. - Quarter-on-quarter, existing mature hospitals have shown about 10-11% sales growth; Raipur hospital has shown 7.5% growth. - Strategy to increase occupancy rates to around 70% to 75% in mature hospitals within 1 to 1.5 years supports volume growth. - Expansion plans include a new 150-bed Jamshedpur hospital commissioning by Q4 FY '27 and pursuing further brownfield/greenfield opportunities, particularly in Eastern India. - Focus on adding high ARPOB (Average Revenue Per Occupied Bed) departments and advanced procedures (robotic surgeries, oncology, cardiology) to improve case mix and revenue per bed. - With occupancy improvement, specialized procedures, and demographic demand, the company anticipates continued revenue growth linked to higher throughput and better case mix.

- Management expects EBITDA breakeven in Raipur Hospital within next 6 months, with full-year FY '27 nearly EBITDA positive. - Jamshedpur hospital commissioning expected by Q4 FY '27, with anticipated INR 3-4 crores loss in the startup phase. - Mature hospitals like Dum Dum, Salt Lake, Agartala, and Howrah are showing double-digit revenue growth, expected to continue. - Occupancy rates targeted to reach around 70% in mature hospitals within 1 to 1.5 years, driving profitability. - ARPOB (Average Revenue Per Occupied Bed) expected to grow with inflation and improved clinical offerings. - Overall, company projects a stable margin with EBITDA of INR 65.1 crores for 9 months FY '26 and aims to build on cost discipline for future profit growth. - Expansion to 1,000 beds by 2027 via organic and inorganic growth to support scaled revenue and earnings growth. - Management optimistic about consistent double-digit growth in the medium term with improving margins.

- Jamshedpur Hospital: - Upcoming 150-bed facility, project work progressing as per schedule. - Capex (~INR75 crores) not yet spent; will commence post developer scope of work. - Expected commissioning by Q4 FY '27. - Expected EBITDA losses of INR3-4 crores during commissioning phase. - Expansion towards 1,000 beds by 2027: - Apart from Jamshedpur, actively evaluating inorganic (brownfield/greenfield) and organic opportunities in Eastern India, including Tier 2 and Tier 3 cities like Bihar, UP, and Orissa. - Focus on technology-led care delivery: - Investment in robotic surgeries, advanced diagnostics, specialized tertiary procedures ongoing. - Raipur Hospital: - Recently commissioned; ramping up clinical capabilities and operational capacity. - Achieving EBITDA breakeven expected within next 6-8 months.

The transcript does not explicitly mention any current or planned fundraising through debt or equity. However, relevant points include: - The company is investing in expanding capacity, including commissioning the Jamshedpur hospital (150 beds), with capex yet to be spent. - Management is actively pursuing and evaluating expansion opportunities, both organic and inorganic, especially in eastern India. - No direct references to raising capital via debt or equity were made during the Q&A or management commentary. - The financial focus includes disciplined cost management, improving margins, and achieving EBITDA breakeven for new hospitals (Raipur and upcoming Jamshedpur). In summary, there is no explicit mention of ongoing or planned debt/equity fundraising in this call transcript.

The transcript does not explicitly mention any details regarding the current or expected order book or pending orders for GPT Healthcare Limited. The discussion primarily focuses on: - Hospital occupancy rates and growth targets. - Expansion plans including upcoming hospitals like Jamshedpur (150 beds) and potential inorganic/organic growth opportunities in Eastern India. - Financial performance and EBITDA losses along with breakeven timelines. - Focus on departments, clinical specialties, and technology investments. - No direct references to order book or pending orders were provided in the call. If you need further details or specifics, please provide additional documents or sections to review.